nodes	percent_of_prediction	percent_of_DWPC	metapath
Alendronate—PTPRE—IL6-mediated signaling events—PIAS3—cervical cancer	0.124	0.664	CbGpPWpGaD
Alendronate—PTPRE—decidua—cervical cancer	0.0489	0.0602	CbGeAlD
Alendronate—PTPN4—uterine cervix—cervical cancer	0.0488	0.0601	CbGeAlD
Alendronate—PTPN4—uterus—cervical cancer	0.0407	0.0501	CbGeAlD
Alendronate—PTPRE—female reproductive system—cervical cancer	0.0385	0.0474	CbGeAlD
Alendronate—PTPN4—female reproductive system—cervical cancer	0.0366	0.045	CbGeAlD
Alendronate—PTPRE—female gonad—cervical cancer	0.035	0.0431	CbGeAlD
Alendronate—PTPRE—vagina—cervical cancer	0.0348	0.0428	CbGeAlD
Alendronate—PTPN4—female gonad—cervical cancer	0.0333	0.041	CbGeAlD
Alendronate—PTPN4—vagina—cervical cancer	0.0331	0.0407	CbGeAlD
Alendronate—PTPRS—female reproductive system—cervical cancer	0.0314	0.0386	CbGeAlD
Alendronate—PTPRS—female gonad—cervical cancer	0.0285	0.0351	CbGeAlD
Alendronate—ATP6V1A—uterine cervix—cervical cancer	0.0241	0.0297	CbGeAlD
Alendronate—ATP6V1A—decidua—cervical cancer	0.023	0.0283	CbGeAlD
Alendronate—ATP6V1A—renal system—cervical cancer	0.0226	0.0278	CbGeAlD
Alendronate—PTPRE—lymph node—cervical cancer	0.0225	0.0277	CbGeAlD
Alendronate—ATP6V1A—endometrium—cervical cancer	0.0218	0.0269	CbGeAlD
Alendronate—PTPN4—lymph node—cervical cancer	0.0214	0.0263	CbGeAlD
Alendronate—ATP6V1A—mammalian vulva—cervical cancer	0.0211	0.026	CbGeAlD
Alendronate—ATP6V1A—uterus—cervical cancer	0.0201	0.0248	CbGeAlD
Alendronate—PTPRS—lymph node—cervical cancer	0.0183	0.0226	CbGeAlD
Alendronate—FDPS—uterine cervix—cervical cancer	0.0182	0.0224	CbGeAlD
Alendronate—ATP6V1A—female reproductive system—cervical cancer	0.0181	0.0223	CbGeAlD
Alendronate—FDPS—decidua—cervical cancer	0.0173	0.0213	CbGeAlD
Alendronate—FDPS—SREBP signalling—YY1—cervical cancer	0.0171	0.0918	CbGpPWpGaD
Alendronate—FDPS—renal system—cervical cancer	0.017	0.0209	CbGeAlD
Alendronate—ATP6V1A—female gonad—cervical cancer	0.0165	0.0203	CbGeAlD
Alendronate—FDPS—endometrium—cervical cancer	0.0164	0.0202	CbGeAlD
Alendronate—ATP6V1A—vagina—cervical cancer	0.0164	0.0201	CbGeAlD
Alendronate—FDPS—mammalian vulva—cervical cancer	0.0159	0.0196	CbGeAlD
Alendronate—PTPRE—IL6-mediated signaling events—STAT3—cervical cancer	0.0155	0.0829	CbGpPWpGaD
Alendronate—FDPS—uterus—cervical cancer	0.0152	0.0187	CbGeAlD
Alendronate—FDPS—female reproductive system—cervical cancer	0.0136	0.0168	CbGeAlD
Alendronate—FDPS—female gonad—cervical cancer	0.0124	0.0153	CbGeAlD
Alendronate—FDPS—vagina—cervical cancer	0.0123	0.0152	CbGeAlD
Alendronate—ATP6V1A—lymph node—cervical cancer	0.0106	0.013	CbGeAlD
Alendronate—FDPS—lymph node—cervical cancer	0.00797	0.00981	CbGeAlD
Alendronate—ATP6V1A—Signaling by Insulin receptor—FGFR3—cervical cancer	0.00388	0.0208	CbGpPWpGaD
Alendronate—FDPS—SREBP signalling—MTOR—cervical cancer	0.0033	0.0177	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—MTOR—cervical cancer	0.00273	0.0146	CbGpPWpGaD
Alendronate—PTPRS—Extracellular matrix organization—CASP3—cervical cancer	0.00266	0.0142	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—WNT2—cervical cancer	0.00165	0.00882	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TAAR6—cervical cancer	0.00148	0.00791	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—WNT5A—cervical cancer	0.00125	0.00668	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—WNT2—cervical cancer	0.00115	0.00618	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CA9—cervical cancer	0.00104	0.00558	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—AKAP13—cervical cancer	0.00101	0.00542	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—WNT5A—cervical cancer	0.000874	0.00468	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—HES1—cervical cancer	0.000718	0.00385	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MTHFR—cervical cancer	0.000631	0.00338	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TERT—cervical cancer	0.000629	0.00337	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—NOTCH2—cervical cancer	0.000613	0.00328	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—FGFR3—cervical cancer	0.000578	0.00309	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—NOTCH1—cervical cancer	0.000542	0.0029	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HES1—cervical cancer	0.000503	0.00269	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TERT—cervical cancer	0.000441	0.00236	CbGpPWpGaD
Alendronate—FDPS—Metabolism—MTHFR—cervical cancer	0.000423	0.00226	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MTOR—cervical cancer	0.000406	0.00218	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CD4—cervical cancer	0.000406	0.00217	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—FGFR3—cervical cancer	0.000404	0.00217	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—NOTCH1—cervical cancer	0.00038	0.00203	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CTNNB1—cervical cancer	0.00036	0.00193	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—STAT3—cervical cancer	0.000314	0.00168	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—EGFR—cervical cancer	0.000285	0.00153	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MTOR—cervical cancer	0.000285	0.00152	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CASP3—cervical cancer	0.000262	0.0014	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CTNNB1—cervical cancer	0.000252	0.00135	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—STAT3—cervical cancer	0.00022	0.00118	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—EGFR—cervical cancer	0.0002	0.00107	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TP53—cervical cancer	0.000168	0.000898	CbGpPWpGaD
Alendronate—Heartburn—Topotecan—cervical cancer	8.65e-05	0.115	CcSEcCtD
Alendronate—Cramp muscle—Topotecan—cervical cancer	3.89e-05	0.0517	CcSEcCtD
Alendronate—Stomatitis—Topotecan—cervical cancer	3.24e-05	0.0431	CcSEcCtD
Alendronate—Haemoglobin—Topotecan—cervical cancer	3e-05	0.0399	CcSEcCtD
Alendronate—Haemorrhage—Topotecan—cervical cancer	2.99e-05	0.0397	CcSEcCtD
Alendronate—Alopecia—Topotecan—cervical cancer	2.64e-05	0.0351	CcSEcCtD
Alendronate—Muscle spasms—Topotecan—cervical cancer	2.5e-05	0.0333	CcSEcCtD
Alendronate—Ill-defined disorder—Topotecan—cervical cancer	2.41e-05	0.0321	CcSEcCtD
Alendronate—Anaemia—Topotecan—cervical cancer	2.4e-05	0.032	CcSEcCtD
Alendronate—Angioedema—Topotecan—cervical cancer	2.38e-05	0.0316	CcSEcCtD
Alendronate—Malaise—Topotecan—cervical cancer	2.35e-05	0.0312	CcSEcCtD
Alendronate—Chest pain—Topotecan—cervical cancer	2.21e-05	0.0294	CcSEcCtD
Alendronate—Myalgia—Topotecan—cervical cancer	2.21e-05	0.0294	CcSEcCtD
Alendronate—Discomfort—Topotecan—cervical cancer	2.19e-05	0.0291	CcSEcCtD
Alendronate—Infection—Topotecan—cervical cancer	2.11e-05	0.028	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Topotecan—cervical cancer	1.93e-05	0.0257	CcSEcCtD
Alendronate—Dyspepsia—Topotecan—cervical cancer	1.87e-05	0.0248	CcSEcCtD
Alendronate—Pain—Topotecan—cervical cancer	1.82e-05	0.0241	CcSEcCtD
Alendronate—Constipation—Topotecan—cervical cancer	1.82e-05	0.0241	CcSEcCtD
Alendronate—Feeling abnormal—Topotecan—cervical cancer	1.75e-05	0.0233	CcSEcCtD
Alendronate—Gastrointestinal pain—Topotecan—cervical cancer	1.74e-05	0.0231	CcSEcCtD
Alendronate—Urticaria—Topotecan—cervical cancer	1.69e-05	0.0224	CcSEcCtD
Alendronate—Abdominal pain—Topotecan—cervical cancer	1.68e-05	0.0223	CcSEcCtD
Alendronate—Body temperature increased—Topotecan—cervical cancer	1.68e-05	0.0223	CcSEcCtD
Alendronate—Hypersensitivity—Topotecan—cervical cancer	1.56e-05	0.0208	CcSEcCtD
Alendronate—Asthenia—Topotecan—cervical cancer	1.52e-05	0.0203	CcSEcCtD
Alendronate—Pruritus—Topotecan—cervical cancer	1.5e-05	0.02	CcSEcCtD
Alendronate—Diarrhoea—Topotecan—cervical cancer	1.45e-05	0.0193	CcSEcCtD
Alendronate—Dizziness—Topotecan—cervical cancer	1.4e-05	0.0187	CcSEcCtD
Alendronate—Vomiting—Topotecan—cervical cancer	1.35e-05	0.0179	CcSEcCtD
Alendronate—Rash—Topotecan—cervical cancer	1.34e-05	0.0178	CcSEcCtD
Alendronate—Dermatitis—Topotecan—cervical cancer	1.34e-05	0.0178	CcSEcCtD
Alendronate—Headache—Topotecan—cervical cancer	1.33e-05	0.0177	CcSEcCtD
Alendronate—Nausea—Topotecan—cervical cancer	1.26e-05	0.0168	CcSEcCtD
